Psoriasis

What are IL-17 Inhibitors?

Biologics targeting IL-17A (secukinumab, ixekizumab) produce rapid, profound skin clearance in moderate-severe plaque psoriasis. They achieve PASI 90 (90% clearance) in the majority of patients — a remarkable improvement over older systemic therapies.

Why China?

• Cost (annual): $8,000-$14,000 (domestic patient assistance) vs. $65,000-$85,000 in the US
• Multiple options: Secukinumab, ixekizumab, netakimab all NMPA-approved
• Dedicated biologic centers: Huashan, Peking Union, Changhai — rheum+derm integration
• Biosimilars emerging: Additional cost reduction over next 1-2 years

Who is a candidate?

• Moderate-severe plaque psoriasis (BSA >10% or PASI >10)
• Psoriatic arthritis
• Ankylosing spondylitis
• Failed or intolerant to conventional systemics + MTX
• Exclude: active TB, active IBD

Outcomes

PASI 75 at 12 weeks: 85-90%. PASI 90: 70-75%. PASI 100 (complete clearance): 40-50%. Rapid onset: significant improvement by Week 2-4. Long-term durability: 5+ years with continued therapy.